NEA Management Company as of Dec. 31, 2025
Portfolio Holdings for NEA Management Company
NEA Management Company holds 27 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Celcuity (CELC) | 18.0 | $353M | 3.5M | 99.74 | |
| Rhythm Pharmaceuticals (RYTM) | 15.9 | $312M | 2.9M | 107.04 | |
| Arcellx Common Stock (ACLX) | 10.1 | $199M | 3.0M | 65.20 | |
| Trevi Therapeutics (TRVI) | 8.4 | $166M | 13M | 12.52 | |
| Savara (SVRA) | 7.5 | $148M | 25M | 6.03 | |
| Zenas Biopharma (ZBIO) | 6.5 | $128M | 3.5M | 36.31 | |
| Monte Rosa Therapeutics (GLUE) | 6.2 | $121M | 7.7M | 15.68 | |
| Mbx Biosciences (MBX) | 5.8 | $114M | 3.6M | 31.54 | |
| Coursera (COUR) | 4.8 | $95M | 13M | 7.36 | |
| Aurinia Pharmaceuticals (AUPH) | 3.2 | $63M | 4.0M | 15.95 | |
| Gossamer Bio (GOSS) | 2.9 | $56M | 18M | 3.10 | |
| CRISPR Therapeutics Namen Akt (CRSP) | 2.8 | $56M | 1.1M | 52.44 | |
| Oric Pharmaceuticals (ORIC) | 1.7 | $34M | 4.1M | 8.18 | |
| Phathom Pharmaceuticals (PHAT) | 1.7 | $33M | 2.0M | 16.59 | |
| CVRX (CVRX) | 0.7 | $14M | 2.0M | 7.10 | |
| X4 Pharmaceuticals | 0.7 | $13M | 3.2M | 4.00 | |
| Champions Oncology Com New (CSBR) | 0.6 | $12M | 1.7M | 6.91 | |
| Black Diamond Therapeutics (BDTX) | 0.6 | $11M | 4.4M | 2.43 | |
| Korro Bio (KRRO) | 0.4 | $8.7M | 1.1M | 8.01 | |
| Inventiva SA Ads (IVA) | 0.3 | $6.8M | 1.5M | 4.65 | |
| Nkarta (NKTX) | 0.3 | $6.6M | 3.6M | 1.85 | |
| Senti Biosciences Com New (SNTI) | 0.2 | $3.9M | 3.8M | 1.04 | |
| Athira Pharma | 0.2 | $3.5M | 464k | 7.57 | |
| Synlogic Com New (SYBX) | 0.2 | $3.3M | 2.9M | 1.12 | |
| Marker Therapeutics Com New (MRKR) | 0.1 | $2.4M | 1.6M | 1.49 | |
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $1.4M | 479k | 2.90 | |
| Imagenebio (IMA) | 0.0 | $345k | 50k | 6.90 |
